2021-09-23T14:50:39-05:00 2020-12-31 131655065 LUTZ AND CARR CPAS LLP 551 FIFTH AVENUE SUITE 400 NEW YORK NY 10176 990 2020-01-01 582492929 LUPUS RESEARCH ALLIANCE INC LUPU 2122182840 275 MADISON AVE 10TH FLOOR NEW YORK NY 10016 DEBRA ROSE CHIEF FIN. AND ADMIN. OFFICER 2122182840 2021-09-21 1 DEBRA ROSE 999009999 LAUREN CRESCI P01268493 2126972299 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z KENNETH M FARBER 275 MADISON AVE 10TH FLOOR NEW YORK NY 10016 53112899 0 X LUPUSRESEARCH.ORG X 1999 NY TO SUPPORT RESEARCH TO PREVENT, TREAT AND CURE LUPUS. 24 24 49 500 0 0 17673622 41539746 1236449 1291193 2148621 1938994 0 20119 21058692 44790052 15505548 23030250 0 0 5172935 5962910 49000 49000 2838968 6083559 5224653 26811042 34266813 -5752350 10523239 71431718 103408141 26661517 41851086 44770201 61557055 X THE LUPUS RESEARCH ALLIANCE LEADS THE WORLD IN TRANSFORMING THE LIVES OF PEOPLE AFFECTED WITH LUPUS BY USING THE POWER OF SCIENCE TO DRIVE NEW TREATMENTS, PREVENT DISEASE PROGRESSION, AND FIND A CURE. 0 0 15417842 14398193 RESEARCH:THE LUPUS RESEARCH ALLIANCE (LRA) IS THE LARGEST NON-GOVERNMENTAL, NON-PROFIT FUNDER OF LUPUS RESEARCH WORLDWIDE. THE ORGANIZATION AIMS TO TRANSFORM TREATMENT BY FUNDING THE MOST INNOVATIVE LUPUS RESEARCH, FOSTERING DIVERSE SCIENTIFIC TALENT, AND DRIVING DISCOVERY TOWARD BETTER DIAGNOSTICS AND IMPROVED TREATMENTS. LRA-FUNDED RESEARCH IS LEADING TO KEY DISCOVERIES THAT ARE IMPROVING DIAGNOSIS AND THERAPIES WHILE ADVANCING TOWARD PREVENTION AND ULTIMATELY A CURE. THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS (BOD) AND SCIENTIFIC ADVISORY BOARD INCLUDE TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE BOARD, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA. SINCE ITS INCEPTION, THE LRA HAS COMMITTED OVER $218 MILLION TO FUND LUPUS RESEARCH PROJECTS. IN 2020 ALONE, OVER $14 MILLION WAS AWARDED IN GRANTS FOR HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE: 1) A NEW INVESTIGATOR INITIATED CLINICAL TRIAL AWARD WAS MADE IN 2020 FOR $1.6MILLION OVER THREE YEARS TO STUDY THE EFFECTS OF THE COVID-19 VACCINES ON LUPUS PATIENTS. AN ADDITIONAL $1.4 MILLION WAS FUNDED BY LUPUS THERAPEUTICS TO THE LUPUS CLINICAL INVESTIGATORS NETWORK PARTICIPATING IN THIS STUDY;2) 5 LUPUS MECHANISMS AND TARGETS AWARD GRANTS (FORMERLY KNOWN AS TARGET IDENTIFICATION IN LUPUS) WERE MADE FOR A TOTAL OF NEARLY $3 MILLION OVER THREE YEARS FOCUSING OF UNDERSTANDING DISEASE MECHANISMS AND IDENTIFYING NEW DRUG TARGETS; 3) 7 LUPUS INNOVATION AWARD GRANTS (FORMERLY KNOWN AS NOVEL RESEARCH PROGRAM) WERE AWARDED FOR A TOTAL OF $2.1 MILLION OVER TWO YEAR FOCUSING ON EARLY-STAGE FUNDAMENTAL RESEARCH INTO DISEASE MECHANISMS; 4) 2 DISTINGUISHED INNOVATOR AWARD GRANTS FOCUS ON UNCOVERING THE UNDERLYING CAUSES OF LUPUS WERE FUNDED FOR A TOTAL OF $2 MILLION OVER TWO YEARS;5) 6 COMMON MECHANISMS GRANTS WERE AWARDED JOINTLY WITH JDRF FOR OVER $1.2 MILLION FOR ONE- AND TWO-YEAR GRANTS;6) 10 ACCELERATOR AWARDS WERE FUNDED FOR A TOTAL OF NEARLY $3 MILLION WITH SUPPORT FROM CELGENE (NOW BRISTOL MYERS SQUIBB). 7) THE LUPUS INSIGHT PRIZE WAS AWARDED FOR $100,000. THIS AWARD RECOGNIZES A LEADING RESEARCHER WHO HAS MADE A MAJOR CONTRIBUTION TO THE FIELD.THE LUPUS RESEARCH ALLIANCE'S UNIQUE FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS WITH THE GOAL OF IMPROVING THE LIVES OF PEOPLE WITH LUPUS IN THE NEAR FUTURE. THROUGH A COMPETITIVE PEER-REVIEW PROCESS PROJECTS BY THE LUPUS RESEARCH ALLIANCE AIM TO TRANSLATE RESULTS FROM THE RESEARCH BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. BECAUSE THE LUPUS RESEARCH ALLIANCE BOARD OF DIRECTORS FUNDS THE ADMINISTRATIVE AND FUNDRAISING EXPENSES, 100% OF ALL OTHER CONTRIBUTIONS GOES TO SUPPORT THE LUPUS RESEARCH ALLIANCE'S LUPUS RESEARCH PROGRAMS. 12839966 8612243 1291193 SCIENTIFIC PROGRAMS:2020 WAS A YEAR OF CONSIDERABLE ACTIVITY WITHIN LUPUS RESEARCH ALLIANCE'S (LRA) SCIENTIFIC PROGRAM EVEN WITH THE PANDEMIC. THE IMPLEMENTATION OF LRA'S SCIENTIFIC STRATEGIC PLAN FOCUSING ON HETEROGENEITY CONTINUED WITH MUCH WORK DONE ON CREATING A LUPUS BIO-REPOSITORY AND REGISTRY. IN 2020, THE LUPUS RESEARCH ALLIANCE DEVELOPED A BUSINESS PLAN FOR LUPUS NEXUS, A PATIENT REGISTRY AND BIOREPOSITORY, TO PROVIDE A GAME-CHANGING CONTRIBUTION TO LUPUS PATIENT-CENTERED RESEARCH. THE DEVELOPMENT OF LUPUS NEXUS WILL CAPITALIZE ON CURRENT STRATEGIC OPPORTUNITIES IN THE LUPUS FIELD BY ENABLING A COLLABORATIVE, DATA-DRIVEN PLATFORM FOR THE RESEARCH COMMUNITY. THE LUPUS NEXUS WILL CATALYZE GLOBAL COLLABORATIONS, RESEARCH INNOVATION AND PRECISION MEDICINE APPROACHES TO ACCELERATE LUPUS DRUG DISCOVERY AND IMPROVE THE QUALITY OF LIFE OF LUPUS PATIENTS BY PROVIDING ACCESS TO PATIENTS' SAMPLES AND DATA TO DELIVER NEW TREATMENTS, PREVENT DISEASE PROGRESSION, AND CURE LUPUS.THE LUPUS RESEARCH ALLIANCE ENCOURAGES CROSS-SECTOR AND CROSS-DISCIPLINE PARTNERSHIPS TO FOSTER THE MOST INNOVATIVE AND PRODUCTIVE RESEARCH ENVIRONMENT. IN 2020, VIRTUAL COLLABORATIVE MEETINGS WERE HELD BY THE LUPUS RESEARCH ALLIANCE WHERE RESEARCHERS WERE ENCOURAGED TO EXCHANGE IDEAS AND HELP THE LUPUS RESEARCH ALLIANCE TARGET NEW RESEARCH OPPORTUNITIES. THIS INCLUDED THE: ANNUAL FORUM FOR DISCOVERY WHERE FUNDED SCIENTISTS AND GUESTS SHARE THEIR PROGRESS; RESEARCH COMMITTEE MEETINGS WHERE MEMBERS OF OUR BOARD OF DIRECTORS AS WELL AS TOP-LEVEL RESEARCHERS DISCUSSED OUR PORTFOLIO AND UPCOMING STRATEGIC STEPS; SCIENTIFIC ADVISORY BOARD MEETINGS WHERE OUR ADVISORS REVIEW GRANT APPLICATION SUBMISSIONS AND DISCUSS FUTURE OVERALL RESEARCH STRATEGY FOR THE ORGANIZATION; LUPUS INDUSTRY COUNCIL MEETINGS WHERE INDUSTRY FOCUSES ON SOLVING SHARED OBSTACLES TO CLINICAL TRIALS; CLINICAL TRIALS AWARENESS FAIRS THAT ENGAGE THE LUPUS COMMUNITY IN UNDERSTANDING, PARTICIPATING IN AND ADVOCATING FOR LUPUS CLINICAL TRIALS; AND LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN) MEETINGS WHERE TOP RESEARCHERS DISCUSS THE DESIGN AND PROGRESS FOR LUPUS CLINICAL TRIALS. THE LUPUS RESEARCH ALLIANCE FOUNDED LUPUS THERAPEUTICS, LLC AS AN AFFILIATE OF THE LRA IN 2018 TO RUN LUCIN TO ADVANCE CLINICAL TRIALS AND FACILITATE THE DEVELOPMENT OF MUCH NEEDED NEW LUPUS TREATMENTS. THE LUPUS RESEARCH ALLIANCE COMMITTED OVER $8.6 MILLION IN 2-YEAR GRANTS IN 2020 TO TOP ACADEMIC CENTERS TO FOSTER CLINICAL TRIAL PARTICIPATION IN LUCIN. LUPUS THERAPEUTICS (LT) CONTINUES TO HAVE A DIVERSE PORTFOLIO OF ONGOING CLINICAL TRIALS WITHIN LUCIN AND IN 2020, THERE WERE FIFTEEN ACTIVE STUDIES MANAGED VIA LUPUS THERAPEUTICS IN CONJUNCTION WITH THE LUCIN NETWORK WITH AN EMPHASIS ON NEW TREATMENTS FOR LUPUS IN PHASE II AND III CLINICAL STUDIES. MOREOVER, LT HAS A HEALTHY PIPELINE OF NEW BUSINESS DEVELOPMENT DISCUSSIONS WITH INDUSTRY RELATED TO PERFORMING ADVISORY SERVICES AND/OR CONDUCTING PROSPECTIVE CLINICAL TRIALS WITHIN THE NETWORK AND COMPLETED 7 CONSULTATIVE ENGAGEMENTS WITH PHARMA IN 2020. 743966 19814 PUBLIC POLICY:THE MAIN GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM ARE TO: EDUCATE MEMBERS OF CONGRESS ABOUT ISSUES OF PRIORITY TO THE LUPUS COMMUNITY; INCREASE FEDERAL FUNDING FOR LUPUS RESEARCH BY INCREASING OVERALL NATIONAL INSTITUTES OF HEALTH (NIH) FUNDS, AND SECURE ADDITIONAL FUNDING FOR LUPUS RESEARCH THROUGH OTHER KEY FEDERAL AGENCIES INCLUDING THE DEPARTMENT OF DEFENSE (DOD). VOLUNTEERS ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LUPUS RESEARCH ALLIANCE ONGOING PUBLIC POLICY PROGRAM EFFORTS, SIGNIFICANT FUNDING FOR LUPUS RESEARCH HAS BEEN OBTAINED UNDER THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP) OPERATED BY THE ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. FIRST, THE LUPUS RESEARCH ALLIANCE WAS RESPONSIBLE FOR PERSUADING CONGRESS TO INCLUDE LUPUS IN ITS LIST OF DESIGNATED DISEASES ELIGIBLE FOR FUNDING OVER THE PAST TEN YEARS IN THE PEER REVIEWED MEDICAL PROGRAM. MOST RECENTLY, LUPUS RESEARCH ALLIANCE ADVOCACY SUCCEEDED IN THE ESTABLISHMENT IN 2017 OF THE LUPUS RESEARCH PROGRAM UNDER THE CDMRP. OVER THE PROGRAM'S FIRST THREE YEARS, $5 MILLION WAS EARMARKED EACH YEAR SPECIFICALLY FOR LUPUS; THROUGH THE LUPUS RESEARCH ALLIANCE'S CONTINUED EFFORTS THIS AMOUNT WAS INCREASED TO $10M IN FISCAL YEARS (FY) 2020 AND 2021 DEFENSE APPROPRIATIONS BILLS OVER FIVE YEARS, $35M WAS SECURED UNDER THIS PROGRAM, AND THE LRA HAS REQUESTED AN INCREASE TO $15M FOR FY 2022.IN 2017, THE LUPUS PATIENT-FOCUSED DRUG DEVELOPMENT (PFDD) INITIATIVE WAS LAUNCHED TO BRING THE VOICE OF THE PATIENT TO DRUG DEVELOPMENT. THIS COLLABORATIVE EFFORT WITH THE LUPUS AND ALLIED DISEASES ASSOCIATION (LADA) AND LUPUS FOUNDATION OF AMERICA (LFA) WAS DESIGNED TO PROVIDE THE FOOD AND DRUG ADMINISTRATION (FDA) WITH PERSPECTIVES FROM PEOPLE WITH LUPUS, ADVOCATES, AND CAREGIVERS TO HELP INFORM THE FDA'S DECISIONS AND OVERSIGHT DURING THE DRUG DEVELOPMENT AND REVIEW PROCESSES. A REPORT WAS SENT TO THE FDA IN SPRING 2018. THE LRA CONTINUES TO WORK TO BRING THE VOICE OF THE PATIENT TO THE DRUG REVIEW PROCESS BY RESPONDING TO RELEVANT CALLS FROM THE FDA FOR COMMENTS. ONGOING ADVOCACY FOCUSES ON ENSURING LEGISLATION THAT SECURES THE FEDERAL FUNDING SUPPORT NECESSARY TO AFFORD INVESTIGATORS THE RESOURCES TO FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE TREATMENT OF LUPUS. EVERY YEAR, THE LRA BRINGS ADVOCATES FROM ACROSS THE COUNTRY TO WASHINGTON DC FOR A DAY OF ADVOCACY TRAINING AND PRE-SCHEDULED MEETINGS WITH LEGISLATORS. THE GOAL IS TO INCREASE AWARENESS OF LUPUS AND THE IMPACT IT HAS ON PEOPLES' DAILY LIVES TO MEMBERS OF CONGRESS AND TO REQUEST THEIR SUPPORT FOR INCREASED FUNDING FOR LUPUS RESEARCH FROM FEDERAL PROGRAMS SUCH AS THE NIH. IN 2020, DUE TO THE COVID-19 PANDEMIC, WE PIVOTED TO A VIRTUAL EVENT, ENCOURAGING ADVOCATES TO REACH OUT WITH PHONE CALLS AND EMAILS. 29001774 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 65 0 1 49 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 24 24 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X X X DEBRA ROSE 6468846000 275 MADISON AVE 10 FLOOR NEW YORK NY 10016 IRA AKSELRAD CO-CHAIR 1.00 X X 0 0 0 RICHARD K DESCHERER CO-CHAIR 1.00 X X 0 0 0 JOSEPH MAURIELLO TREASURER 1.00 X X 0 0 0 BRENDA BLACKMON SECRETARY 1.00 X X 0 0 0 BISHOP RUDY V CARLTON DIRECTOR 1.00 X 0 0 0 JEROME CHAZEN DIRECTOR 1.00 X 0 0 0 WILLIE COLON DIRECTOR 1.00 X 0 0 0 THOMAS O DANIEL DIRECTOR 1.00 X 0 0 0 JENNIE DESCHERER DIRECTOR 1.00 X 0 0 0 KATEY DRISCOLL DIRECTOR 1.00 X 0 0 0 SIR MARC FELDMANN DIRECTOR 1.00 X 0 0 0 MOTI FERDER DIRECTOR 1.00 X 0 0 0 JOE GERMANOTTA DIRECTOR 1.00 X 0 0 0 DAVID KIES DIRECTOR 1.00 X 0 0 0 DANIEL LAVECCHIA DIRECTOR 1.00 X 0 0 0 LOUIS LUCIDO DIRECTOR 1.00 X 0 0 0 MOLLY MCCABE DIRECTOR 1.00 X 0 0 0 NADEEM MEGHJI DIRECTOR 1.00 X 0 0 0 WILLIAM J MULVIHILL DIRECTOR 1.00 X 0 0 0 ROBERT SEDER MD DIRECTOR 1.00 X 0 0 0 DANIEL J WALLACE DIRECTOR 1.00 X 0 0 0 WILLIAM WOLFE DIRECTOR 1.00 X 0 0 0 CAROL WEISMAN DIRECTOR 1.00 X 0 0 0 SPENCER ZWICK DIRECTOR 1.00 X 0 0 0 KENNETH M FARBER CEO AND PRESIDENT 40.00 X 429099 0 73996 DEBRA ROSE CHIEF FINANCE OFFICER 40.00 X 205396 0 39787 ANDREA O'NEILL EXECUTIVE DIRECTOR 40.00 X 261568 0 45243 ALBERT ROY EXECUTIVE DIRECTOR, LUCIN 40.00 X 273012 0 63988 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 40.00 X 298364 0 57474 DIANE GROSS NATIONAL DIRECTOR OF ADVOCACY 40.00 X 139098 0 39397 MARGY MEISLIN EDITORIAL & PR DIRECTOR 40.00 X 133100 0 35416 DOREY NEILINGER SENIOR DIRECTOR OF PHILANTROPHY 40.00 X 168333 0 34323 PENELOPE MITCHELL DIRECTOR OF COMMUNICATIONS 40.00 X 164404 0 18455 JONATHAN MARKS DIRECTOR OF CORPORATE DEVELOPMENT 40.00 X 143580 0 47893 2215954 0 455972 12 0 1 0 KIM KAISER & ASSOCIATES LLC 4001 SANTA BARBARA BLVD 405 NAPLES FL 34104 PHARMA RELATIONS CONSULTANT 248755 MCS HEALTHCARE PR 110 ALLEN ROAD SUITE 300 BASKING RIDGE NJ 07921 PUBLIC RELATIONS CONSULTANT 143600 AMPEL BIOSOLUTIONS LLC 250 WEST MAIN STREET SUITE 300 CHARLOTTESVILLE VA 22902 LUCIN CLINICAL TRIALS 142261 SCHANER & LUBITZ PLLC 4550 MONTGOMERY AVENUE SUITE 1100N BETHESDA MD 20814 CLINICAL TRIALS ATTORNEY 116106 CAVAROCCHI RUSCIO DENNIS & ASSOCIATES L 600 MARLAND AVE SW SUITE 835 W WASHINGTON DC 20024 PUBLIC POLICY CONSULTANTS 102000 5 3898924 37640822 10190725 41539746 LUCIN CONSULTING REVENUE 900099 1291193 1291193 1291193 1594271 1594271 8036504 470564 7668845 493500 367659 -22936 344723 344723 160502 3898924 160502 0 SUBLET INCOME 900099 20119 20119 20119 44790052 1291193 0 1959113 20997003 20997003 19814 19814 2013433 2013433 1672760 845775 372145 454840 3134963 1493016 709403 932544 231301 110865 50092 70344 608262 291586 138793 177883 315624 153207 71004 91413 135083 88392 24148 22543 69772 69772 111804 111804 49000 49000 161535 161535 1241114 805544 250610 184960 112546 53413 40943 18190 547297 304900 154649 87748 1094893 591902 219892 283099 137298 97722 15291 24285 314148 275098 32117 6933 173375 84158 39004 50213 64154 38795 11086 14273 CLINICAL STUDIES 509267 509267 PRINTING & PUBLICATIONS 170699 20050 14630 136019 POSTAGE, SHIPPING & DEL 98197 5169 11123 81905 DATA PROCESSING 95564 24205 5781 65578 187907 66656 34053 87198 34266813 29001774 2426071 2838968 3724504 3877555 873961 846030 2579649 15931284 373770 545275 162892 193080 1122584 731757 494479 390827 61719649 80441611 398731 708544 1104083 473935 71431718 103408141 438885 511502 25422502 39843096 698800 800130 797688 26661517 41851086 X 39293680 45047938 5476521 16509117 44770201 61557055 71431718 103408141 X 10523239 6026720 236895 X 0 1 X 1 0 X 19101537 23693133 15396535 17673622 41539746 117404573 19101537 23693133 15396535 17673622 41539746 117404573 56723727 60680846 1227336 1314981 1336303 1445946 1614390 6938956 -440 204 -236 124343293 4106523 0.48800 0.58960 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 743966 743966 33505652 34249618 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 776350 788377 846235 743966 3154928 250000 250000 250000 250000 1000000 1500000 51813456 6226708 1453727 56586437 46122925 8404231 2713456 51813456 51742397 -2936193 2683279 46122925 45863827 8478913 2600343 51742397 44173045 4257605 2566823 45863827 1.00000 0 0 424912 185293 239619 697672 546464 151208 390827 DEFERRED RENT 797688 797688 50874937 6026720 219700 6246420 44628517 161535 161535 44790052 34088083 0 34088083 161535 17195 178730 34266813 PART V, LINE 4: BOARD DESIGNATED (QUASI) ENDOWMENT FUND INCOME TO BE USED FOR RESEARCH PROGRAM GRANTS. PRINCIPAL TO REMAIN INTACT UNLESS HIGH PRIORITY LUPUS RESEARCH PROJECTS NEED TO BE FUNDED THAT COULD NOT BE FUNDED OTHERWISE. PART XII, LINE 4B - OTHER ADJUSTMENTS: RETURN OF GRANTS & ADJUSTMENTS 17,195. PART PART XII, LINE 4B UNUSED PORTIONS OF GRANTS RETURNED TO LRA THAT WERE PAID IN PREVIOUS YEARS IN THE AMOUNT OF $17,195. THESE AMOUNTS ARE RECONCILING ITEMS BETWEEN THE REVENUE AND EXPENSES FROM THE AUDITED FINANCIAL STATEMENTS AND THOSE REPORTED ON FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS 310000 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS 1154745 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS 548688 0 0 0 0 0 0 2013433 0 2013433 NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 160000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 34745 CHECK BOOK EAST ASIA AND THE PACIFIC LUPUS RESEARCH 310000 CHECK BOOK EAST ASIA AND THE PACIFIC LUPUS RESEARCH 7406 CHECK BOOK EUROPE (INCLUDING ICELAND & GREENLAND) LUPUS RESEARCH 299706 CHECK BOOK EUROPE (INCLUDING ICELAND & GREENLAND) LUPUS RESEARCH 241576 CHECK BOOK 5 7 0 0 0 0 0 0 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, THE SPONSORING INSTITUTION (SI) MUST AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING FORUM FOR DISCOVERY. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OF PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT: A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THIS GRANT. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THE FOLLOWING STATEMENT SHOULD APPEAR AT THE CONCLUSION OF THE LETTER OF ACCEPTANCE, "I AGREE TO ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE RESEARCH PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LUPUS RESEARCH ALLIANCE." IF AN EXTENSION IS AWARDED ADDITIONAL INTERIM PROGRESS REPORTS AND BUDGET RECONCILIATIONS ARE REQUIRED TO BE SUBMITTED. AT THE END OF THE GRANT A FINAL PROGRESS REPORT AND BUDGET RECONCILIATION IS REQUIRED TO BE SUBMITTED, UNSPENT AMOUNTS ARE TO BE RETURNED TO THE LRA. ALL SIS RECEIVE A PAYMENT AND DELIVERABLE SCHEDULE AND THE PROJECT IS MONITORED BY: O PERIODIC PROGRESS REPORTS O PERIODIC BUDGET RECONCILIATIONS ALL PUBLICATIONS RELATED TO THE GRANT ARE TO BE SUBMITTED TO THE LRA THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND VERBAL OR POSTER PRESENTATIONS THE SI MUST SUBMIT A COPY OF THE IRS OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI PART III ACCOUNTING METHOD: X X X X X 1 DS CONSULTING GROUP 845 THIRD AVENUE 6TH FLOOR NEW YORK NY 10022 SPECIAL EVENT CONSULTANT NY GALA 1 3057745 49000 3057754 3057745 49000 3057754 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX VT VA WA WV WI WY GALA CELEBRATION 3254023 3131249 122774 28630 94144 WALK-A-THONS 805403 767675 37728 37728 4059426 3898924 160502 28630 131872 160502 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) DS CONSULTING PLANNED AND MANAGED ALR'S GALA EVENT. CONTRACT AMOUNT FOR THE PERIOD COVERING 1/1/20 - 12/31/20 WAS $49,000 PLUS REIMBURSABLE EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 160000 BOOK LUPUS RESEARCH BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVE SEATTLE WA 98101 910653422 501(C)(3) 574469 BOOK LUPUS RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 160000 BOOK LUPUS RESEARCH BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR BOSTON MA 02115 042312909 501(C)(3) 273298 BOOK LUPUS RESEARCH CHILDREN'S HOSPITAL PHILADELPHIA 3401 CIVIC CENTER BOULEVARD PHILADELPHIA PA 19104 231352166 501(C)(3) 291389 BOOK LUPUS RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 154 HAVEN AVE 2ND FL NEW YORK NY 10032 133598093 501(C)(3) 160000 BOOK LUPUS RESEARCH EMORY UNIVERSITY 1762 CLIFTON RD NE ATLANTA GA 30322 580566256 501(C)(3) 1182854 BOOK LUPUS RESEARCH HOSPITAL FOR SPECIAL SURGERY 535 E 70TH STREET NEW YORK NY 10021 131624135 501(C)(3) 862647 BOOK LUPUS RESEARCH JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)(3) 946854 BOOK LUPUS RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 402824 BOOK LUPUS RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 151389 BOOK LUPUS RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON SC 29425 576028985 SECTION 115 - SC STA 160000 BOOK LUPUS RESEARCH NATIONAL MINORITY QUALITY FORUM INC 1201 15TH STREET NW SUITE 340 WASHINGTON DC 20005 311750942 501(C)(3) 90666 BOOK LUPUS RESEARCH NATIONAL KIDNEY FOUNDATION 30 EAST 33RD STREET NEW YORK NY 10016 131673104 501(C)(3) 115000 BOOK LUPUS RESEARCH NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 754655 BOOK LUPUS RESEARCH NORTHWELL HEALTH - DIVISION OF RHEUMATOLOGY 972 BRUSH HOLLOW RD 5TH FL WESTBURY NY 11590 112673595 501(C)(3) 160000 BOOK LUPUS RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167818 501(C)(3) 497509 BOOK LUPUS RESEARCH OKLAHOMA MEDICAL RESEARCH FOUNDATION 825 NE 13TH STREET OKLAHOMA CITY OK 73104 730580274 501(C)(3) 1333668 BOOK LUPUS RESEARCH PENNSYLVANIA STATE UNIVERSITY ONE OLD MAIN UNIVERSITY PARK PA 16802 246000376 501(C)(3) 160000 BOOK LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA IRVINE 5171 CALIFORNIA AVENUE STE 150 IRVINE CA 92697 952226406 501(C)(3) 160000 BOOK LUPUS RESEARCH RUSH UNIVERSITY MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 160000 BOOK LUPUS RESEARCH STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 645648 BOOK LUPUS RESEARCH ST JUDE CHILDREN'S HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 3314 BOOK LUPUS RESEARCH TEMPLE UNIVERSITY 1801 N BROAD STREET PHILADELPHIA PA 19122 231365971 501(C)(3) 160000 BOOK LUPUS RESEARCH THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 169525 BOOK LUPUS RESEARCH THE METROHEALTH SYSTEM 2500 METROHEALTH DRIVE CLEVELAND OH 44109 346004382 SECTION 115 - OH STA 160000 BOOK LUPUS RESEARCH THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 311702164 SECTION 115 - OH STA 160000 BOOK LUPUS RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 501(C)(3) 160000 BOOK LUPUS RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC0934 LA JOLLA CA 92093 956006144 501(C)(3) 573472 BOOK LUPUS RESEARCH THE RESEARCH FOUNDATION OF SUNY 35 STATE STREET ALBANY NY 12201 141368361 501(C)(3) 160000 BOOK LUPUS RESEARCH THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE STE 501 CHICAGO IL 60637 362177139 501(C)(3) 722396 BOOK LUPUS RESEARCH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 6000 FELDWOOD ROAD COLLEGE PARK GA 30349 566001393 501(C)(3) 210000 BOOK LUPUS RESEARCH TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER 3601 4TH STREET LUBBOCK TX 79430 752668014 TX STATE GOVERNMENT 555655 BOOK LUPUS RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 501(C)(3) 454576 BOOK LUPUS RESEARCH UNIVERISTY OF SOUTHERN CALIFORNIA 1640 MARENGO STREET 7TH FL LOS ANGELES CA 90033 951642394 501(C)(3) 160000 BOOK LUPUS RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 160396 BOOK LUPUS RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 2200 UNIVERSITY HALL BERKELEY CA 94720 946036493 501(C)(3) 285000 BOOK LUPUS RESEARCH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS 3100 MARINE ST 6TH FL BOULDER CO 80309 846000555 501(C)(3) 151389 BOOK LUPUS RESEARCH UNIVERSITY OF FLORIDA 207 TIGERT HALL GAINESVILLE FL 32611 596002052 FL STATE GOVERNMENT 160000 BOOK LUPUS RESEARCH UNIVERSITY OF HOUSTON 4800 CALHOUN ROAD HOUSTON TX 77004 746001399 501(C)(3) 291389 BOOK LUPUS RESEARCH UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGON STREET 4TH FL BALTIMORE MD 21201 521830242 SECTION 115 - MD STA 160000 BOOK LUPUS RESEARCH UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167325 MA STATE GOVERNMENT 166781 BOOK LUPUS RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY GABLES ONE TOWER 650 CORAL GABLES FL 33146 590624458 501(C)(3) 160000 BOOK LUPUS RESEARCH UNIVERSITY OF MICHIGAN 503 THOMPSON STREET ANN ARBOR MI 48109 386006309 501(C)(3) 754703 BOOK LUPUS RESEARCH UNIVERSITY OF MISSISSIPPI MEDICAL CENTER 2500 NORTH STATE STREET JACKSON MS 39216 646008520 501(C)(3) 160000 BOOK LUPUS RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 160000 BOOK LUPUS RESEARCH UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING ROCHESTER NY 14627 160743209 501(C)(3) 157520 BOOK LUPUS RESEARCH UNIVERSITY OF TEXAS SAN ANTONIO 7703 FLOYD CURL DRIVE SAN ANTONIO TX 782293900 746000203 TX STATE GOVERNMENT 3314 BOOK LUPUS RESEARCH UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 SECTION 115 - WA STA 158397 BOOK LUPUS RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 746000203 TX STATE GOVERNMENT 166857 BOOK LUPUS RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DRIVE NASHVILLE TN 37232 352528741 501(C)(3) 458795 BOOK LUPUS RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 185000 BOOK LUPUS RESEARCH WALLACE RHEUMATIC STUDIES CENTER LLC 8737 BENVERLY BLVD STE 301 W HOLLYWOOD CA 90048 455434561 501(C)(3) 160000 BOOK LUPUS RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 3455249 BOOK LUPUS RESEARCH YALE UNIVERSITY BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 590405 BOOK LUPUS RESEARCH 45 10 LUPUS EMERGENCY GRANT - $500 MAX PER PERSON 45 19814 BILLS LUPUS EMERGENCY GRANT - $500 MAX PER PERSON PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, THE SPONSORING INSTITUTION (SI) MUST AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING FORUM FOR DISCOVERY. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OF PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT: A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THIS GRANT. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THE FOLLOWING STATEMENT SHOULD APPEAR AT THE CONCLUSION OF THE LETTER OF ACCEPTANCE, "I AGREE TO ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE RESEARCH PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LUPUS RESEARCH ALLIANCE." IF AN EXTENSION IS AWARDED ADDITIONAL INTERIM PROGRESS REPORTS AND BUDGET RECONCILIATIONS ARE REQUIRED TO BE SUBMITTED. AT THE END OF THE GRANT A FINAL PROGRESS REPORT AND BUDGET RECONCILIATION IS REQUIRED TO BE SUBMITTED, UNSPENT AMOUNTS ARE TO BE RETURNED TO THE LRA. ALL SIS RECEIVE A PAYMENT AND DELIVERABLE SCHEDULE AND THE PROJECT IS MONITORED BY: O PERIODIC PROGRESS REPORTS O PERIODIC BUDGET RECONCILIATIONS ALL PUBLICATIONS RELATED TO THE GRANT ARE TO BE SUBMITTED TO THE LRA THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND VERBAL OR POSTER PRESENTATIONS THE SI MUST SUBMIT A COPY OF THE IRS OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI X X X X X 0 0 0 0 0 0 0 0 0 KENNETH M FARBER CEO AND PRESIDENT 372500 0 50000 0 6599 0 28000 0 45996 0 503095 0 0 0 DEBRA ROSE CHIEF FINANCE OFFICER 189134 0 15000 0 1262 0 21047 0 18740 0 245183 0 0 0 ANDREA O'NEILL EXECUTIVE DIRECTOR 220000 0 40000 0 1568 0 26733 0 18510 0 306811 0 0 0 ALBERT ROY EXECUTIVE DIRECTOR, LUCIN 231790 0 40000 0 1222 0 20860 0 43128 0 337000 0 0 0 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 257066 0 40000 0 1298 0 22749 0 34725 0 355838 0 0 0 DIANE GROSS NATIONAL DIRECTOR OF ADVOCACY 137737 0 500 0 861 0 13420 0 25977 0 178495 0 0 0 MARGY MEISLIN EDITORIAL & PR DIRECTOR 128750 0 1000 0 3350 0 12600 0 22816 0 168516 0 0 0 DOREY NEILINGER SENIOR DIRECTOR OF PHILANTROPHY 164250 0 1000 0 3083 0 17713 0 16610 0 202656 0 0 0 PENELOPE MITCHELL DIRECTOR OF COMMUNICATIONS 161050 0 1000 0 2354 0 2381 0 16074 0 182859 0 0 0 JONATHAN MARKS DIRECTOR OF CORPORATE DEVELOPMENT 141900 0 750 0 930 0 15224 0 32669 0 191473 0 0 0 X 8 10190725 AVG STOCK VALUE 0 1 1 PART I, LINE 32B: LRA HAS AN ACCOUNT WITH MORGAN STANLEY, WHICH LRA USES TO SELL THE CONTRIBUTIONS IT RECEIVES THOUGH STOCKS. FORM 990, PART VI, SECTION A, LINE 2 NEIL J. BURMEISTER (DIRECTOR) AND IRA AKSELRAD (DIRECTOR) HAVE A BUSINESS RELATIONSHIP. RICHARD K. DESCHERER (CO-CHAIR) AND JENNIE DESCHERER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B AFTER PREPARATION BY OF FORM 990 BY LRA'S AUDITOR, LUTZ AND CARR, THE 990 IS REVIEWED BY THE LRA'S SENIOR OFFICERS, THE CHIEF FINANCE OFFICER AND THE PRESIDENT. THE FINANCE AND AUDIT COMMITTEE OF THE BOARD THEN MEETS TO REVIEW THE 990 BEFORE FILING AND APPROVES FOR FILING WITH ANY NOTED CHANGES. A DRAFT OF THE 990 IS THEN SENT OUT TO THE FULL BOARD FOR COMMENT PRIOR TO FILING WITH THE IRS. THE FINAL FORM 990 IS PRESENTED TO THE FULL BOARD AT THE SEPTEMBER MEETING. FORM 990, PART VI, SECTION B, LINE 12C THE GOVERNANCE COMMITTEE OF THE BOARD IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST. AN ANNUAL CONFLICT OF INTEREST DISCLOSURE FORM IS REQUIRED TO BE FILLED OUT EACH YEAR BY BOARD MEMBERS, OFFICERS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTED THE BOARD IN FULFILLING ITS OVERSIGHT RESPONSIBILITIES RELATING TO THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND OTHER EXECUTIVE OFFICERS; AND PROVIDED RECOMMENDATIONS REGARDING MANAGEMENT SUCCESSORS. ANNUALLY THE COMMITTEE REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY FOR THE PRESIDENT AND OTHER OFFICERS/KEY EMPLOYEES. IN 2020, THE COMMITTEE REVIEWED AND APPROVED BASE SALARIES, ANNUAL MERIT ADJUSTMENTS AND BONUSES FOR ALL STAFF. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND ON GUIDESTAR.ORG FORM 990, PART XI, LINE 9: REFUND OF GRANTS 17,195. CANCELLED GRANTS 219,700. FORM 990, PART V, QUESTION 2A THE LRA CONTRACTS WITH TRINET AMBROSE, A PROFESSIONAL EMPLOYER ORGANIZATION (PEO), TO PROVIDE PAYROLL AND BENEFITS AS A CO-EMPLOYER WITH THE LRA. LRA PAYROLL AND BENEFITS ARE ADMINISTERED BY AMBROSE AS APPROVED BY LRA OFFICERS. LRA PAYROLL IS THEREFORE UNDER THE AMBROSE EIN: 13-3867443 AND W-2'S ARE PREPARED UNDER THAT EIN BY TRINET AMBROSE. LUPUS THERAPEUTICS LLC 2550 SOUTH CLARK SUITE 670 ARLINGTON VA 22202 823984908 LRA'S SCIENTIFIC PROGRAMS VA 1449194 13450692 YES